Amarin (AMRN) Competitors $16.07 +0.42 (+2.65%) As of 03:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. AVDL, CVAC, CALT, XERS, PAHC, COLL, NTLA, LENZ, PHVS, and SNDXShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Avadel Pharmaceuticals (AVDL), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Xeris Biopharma (XERS), Phibro Animal Health (PAHC), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), LENZ Therapeutics (LENZ), Pharvaris (PHVS), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Its Competitors Avadel Pharmaceuticals CureVac Calliditas Therapeutics AB (publ) Xeris Biopharma Phibro Animal Health Collegium Pharmaceutical Intellia Therapeutics LENZ Therapeutics Pharvaris Syndax Pharmaceuticals Avadel Pharmaceuticals (NASDAQ:AVDL) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations. Do analysts prefer AVDL or AMRN? Avadel Pharmaceuticals presently has a consensus target price of $18.67, suggesting a potential upside of 38.73%. Amarin has a consensus target price of $12.00, suggesting a potential downside of 25.67%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Avadel Pharmaceuticals is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is AVDL or AMRN more profitable? Avadel Pharmaceuticals has a net margin of -1.32% compared to Amarin's net margin of -47.22%. Avadel Pharmaceuticals' return on equity of -3.73% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-1.32% -3.73% -1.73% Amarin -47.22%-21.18%-15.00% Do insiders and institutionals have more ownership in AVDL or AMRN? 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 5.2% of Avadel Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, AVDL or AMRN? Avadel Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Amarin has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Which has better valuation and earnings, AVDL or AMRN? Avadel Pharmaceuticals has higher earnings, but lower revenue than Amarin. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$221.08M5.91-$48.83M-$0.03-448.50Amarin$228.61M1.46-$82.18M-$3.67-4.40 Does the media prefer AVDL or AMRN? In the previous week, Avadel Pharmaceuticals had 6 more articles in the media than Amarin. MarketBeat recorded 8 mentions for Avadel Pharmaceuticals and 2 mentions for Amarin. Amarin's average media sentiment score of 0.96 beat Avadel Pharmaceuticals' score of 0.42 indicating that Amarin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAvadel Pharmaceuticals beats Amarin on 14 of the 17 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$334.36M$3.13B$5.72B$9.77BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-4.4020.9330.9025.26Price / Sales1.46231.60403.8188.28Price / CashN/A41.5625.2228.45Price / Book0.689.749.516.00Net Income-$82.18M-$54.74M$3.26B$265.34M7 Day Performance8.07%7.94%4.48%2.84%1 Month Performance2.05%7.52%5.19%1.58%1 Year Performance30.90%17.41%31.75%25.40% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.254 of 5 stars$16.07+2.7%$12.00-25.3%+26.9%$333.33M$228.61M-4.39360Positive NewsAVDLAvadel Pharmaceuticals2.8103 of 5 stars$12.79+0.3%$18.67+45.9%-14.1%$1.24B$194.45M-426.3370CVACCureVac4.6843 of 5 stars$5.43-0.2%$6.83+25.8%+69.1%$1.22B$523.70M5.90880Upcoming EarningsShort Interest ↓CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180XERSXeris Biopharma3.4026 of 5 stars$7.20+5.3%$6.25-13.2%+185.5%$1.16B$203.07M-34.28290Insider TradePAHCPhibro Animal Health3.5863 of 5 stars$28.54+1.6%$24.40-14.5%+69.9%$1.16B$1.02B36.591,940COLLCollegium Pharmaceutical2.7742 of 5 stars$36.14+3.5%$42.33+17.1%+7.0%$1.14B$631.45M34.75210Insider TradeNTLAIntellia Therapeutics4.516 of 5 stars$10.74-0.5%$30.68+185.7%-51.4%$1.11B$57.88M-2.29600LENZLENZ Therapeutics2.0297 of 5 stars$38.77+11.8%$49.60+27.9%+66.4%$1.11B$5M-20.41110Gap UpHigh Trading VolumePHVSPharvaris2.728 of 5 stars$20.84+3.6%$36.20+73.7%+18.9%$1.09BN/A-6.9230News CoverageEarnings ReportShort Interest ↓Analyst RevisionSNDXSyndax Pharmaceuticals4.0443 of 5 stars$12.51+0.2%$36.91+195.0%-21.0%$1.08B$23.68M-3.22110 Related Companies and Tools Related Companies Avadel Pharmaceuticals Alternatives CureVac Alternatives Calliditas Therapeutics AB (publ) Alternatives Xeris Biopharma Alternatives Phibro Animal Health Alternatives Collegium Pharmaceutical Alternatives Intellia Therapeutics Alternatives LENZ Therapeutics Alternatives Pharvaris Alternatives Syndax Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 8/18/2025 by MarketBeat.com Staff From Our Partners"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access